Ney Carter Borges: Randomized Trial of the Vascular Effects of Low-Dose Colchicine in High-Risk Type 2 Diabetes
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:
“Colchicine and Arterial Stiffness in High-Risk Type 2 Diabetes: A Randomized Trial Perspective
This randomized, double-blind, placebo-controlled trial evaluates the vascular effects of low-dose colchicine in patients with type 2 diabetes at elevated cardiovascular risk.
Over a 26-week period, 100 participants were assigned to colchicine 0.5 mg daily or placebo, with arterial stiffness assessed via carotid–femoral pulse wave velocity (cfPWV) as the primary endpoint.
The study demonstrates a statistically significant reduction in arterial stiffness progression with colchicine when adjusted for mean arterial pressure (ΔcfPWV minus 0.7 m/s; 95% CI minus 1.3 to minus 0.1; p equal to 0.03), suggesting a potential mechanistic link between anti-inflammatory therapy and vascular compliance improvement.
Notably, crude analyses without adjustment did not reach statistical significance, highlighting the hemodynamic interplay between blood pressure and arterial stiffness.
Secondary outcomes revealed no meaningful impact on 24-hour ambulatory blood pressure or albuminuria, indicating that colchicine’s vascular benefits may occur independently of systemic hemodynamic or renal effects.
Additionally, while a modest reduction in C-reactive protein was observed, other inflammatory biomarkers remained unchanged, suggesting a selective or limited anti-inflammatory modulation.
Clinically, these findings are relevant given that a 1.0 m/s increase in cfPWV is associated with approximately 15% higher cardiovascular risk.
Thus, the observed reduction may translate into meaningful long-term benefits, although this remains speculative.
In conclusion, colchicine appears to attenuate arterial stiffness progression in high-risk diabetic populations, reinforcing its role as a potential adjunctive strategy in residual cardiovascular risk reduction, pending confirmation from larger outcome-driven trials.”
Other posts featuring Ney Carter Borges on Hemostasis Today.
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers
-
May 12, 2026, 15:21Joseph Mmwa: Blood Donation Debate Sparks Concern Across Kenya